Facebook
Twitter
LinkedIn
WhatsApp

Stage 4 Cancer

Stage 4, Stage IV metastatic cancer

“Metastases cancer” or stage 4 cancer, is the medical term for describing a condition where a tumor originating in a certain organ, “primary tumor”, is identified in another organ or in a distant location from the original organ, e.g., metastases of breast cancer can be found in the lungs, brain, bones and liver.

It is important to note, metastases are the same type of the original primary tumor, even if its location is in distant organs and so are the treatments regarded as such, for example, a treatment for a metastatic lung cancer that has spread to the liver, is determined by the treatment for metastatic lung cancer and not by the treatment for liver cancer.

Metastases formation

Cancer cells of the primary tumor can be released into the bloodstream and lymphatic system and circulate to distant organs or adjacent organs and tissues to the primary tumor and “settle” in them and grow.

There are different types of cancer which is known where metastases can be formed, for example,

  • Breast cancer can spread to the bones, brain, liver and lungs
  • Lung cancer can spread to the brain, bones, liver and kidney
  • Prostate cancer can spread to the bones
  • Colon cancer, rectal cancer, colorectal cancer can spread to the liver and lungs
Breast cancer can spread to the bones, brain, liver and lungs
Breast cancer can spread to the bones, brain, liver and lungs

Stage IV metastatic cancer and recovery

In the vast majority of the metastatic cases, the treatments do not cure. Treatment goals are slowing tumor growth rate, prolonging life and reducing the symptoms of the disease, improving the quality of life of the patient.

The efficacy of the treatments is affected by many factors, among them are the type of cancer, number of metastases (also called “lesions”) and their location, how much cancer the patient has in his or her body, growth rate of the tumor lesions, medical history of the patient, background diseases, microenvironment between the tumor cells themselves, resistance the tumor has developed to previous treatments and other.

Advanced treatments and clinical trials for stage 4

The National Cancer Institute (NCI) highlights the fact that for a certain group of metastatic cancer patients, the best treatment option is to join one of the many clinical trials existing worldwide aiming to increase their chances of therapeutic success.

This is also recommended by the USA national comprehensive cancer network, NCCN,  (USA national comprehensive cancer network)

“Patients with cancer should be encouraged to participate in clinical trials during all aspects of their diagnosis and treatment”

Currently, every patient will be offered the standard protocols described above. Sometimes the oncologist may suggest integrating these therapies with trials carried out in the Institute.

Advances in cancer therapies may be found in clinical trials prescribing cutting edge, interesting drugs, some of which have already been recognized by the FDA (US Food & Drug Administration) as “breakthrough treatments” and require further information input before being finally and fully approved.

An entire world of clinical trials and compassionate drugs and treatments are open and available worldwide. It is important to know which cutting edge treatments exist which patients can gain far more from them than the standard care offered.

For most patients with stage 4 metastatic cancer, current treatments are insufficiently effective. This gives rise to the need for innovative strategies with greater efficacy in fighting the disease.

Read our publications on innovative treatments for stage 4 metastatic cancer:

To check if our service suits your case
We need to talk

Improve therapeutic outcomes, prolong life and quality of life, is our main business.
We support access to and expand cancer treatments beyond the standard of care, with the most advanced and innovative treatment options in the world, personally matching the individual cancer patient’s medical condition and with the support of top tier oncologists.

Article categories

קטגוריות המאמרים

Popular topics

Facebook
Twitter
LinkedIn
WhatsApp

A novel drug gets Breakthrough Designation in combination with Opdivo® in Melanoma

Background

Bempegaldesleukin, NKTR-214, and nivolumab, Opdivo, was granted breakthrough deisgnation by the FDA for the first line treatment of patients with previously untreated unresectable or metastatic melanoma.

Bempegaldesleukin, NKTR-214, is a substance designed to stimulate the patient’s own immune system to fight cancer.

In melanoma, Opdivo is FDA approved as a single agent for the treatment of patients with unresectable or metastatic disease, and also in combination with Ipilimumab, Yervoy, for the treatment of patients with unresectable or metastatic disease.

53% of Melanoma patients responded to the combination of NKTR-214 and Opdivo and 34% reached a complete remission of the disease. This ongoing phase I/II PIVOT-02 trial is the basis for the FDA deisgination.

What is breakthrough designation?

When preliminary clinical trials indicate that a therapy may offer substantial treatment advantages over existing options for patients with serious or life-threatening diseases, the FDA grants the therapy a breakthrough designation. This designation allows the FDA to expedite the review process and if the FDA is convinced about the data and results of the clinical trials, the therapy is approved and become available to patients in a much shorter time.

About PIVOT-02 trial

In the multicenter PIVOT-02 trial, there was a range of solid tumors. In the melanoma cohort, 41 patients were enrolled and received ≥1 dose of NKTR-214/Opdivo. As of the data cutoff date, which was March 29, 2019, 38 patients were evaluable for efficacy; 3 patients had discontinued prior to the first scan due to an unrelated treatment adverse event and patient decision.

Trial findings

Interim findings were presented at the ASCO Annual Meeting 2019 two months ago and showed that 53% of Melanoma patients responded to the combination of NKTR-214 and Opdivo and 34% reached a complete remission of the disease.

The disease control rate, which is the total percentage of Melanoma patients who responded to the combination including minor response and stable disease, was 74%.

In PD-L1–positive, PD-L1–negative, and PD-L1–unknown tumors, the responses were 62%, 43%, and 33%, respectively.

There was a 100% reduction in target lesions in 42% of patients.

Overall, responses were observed regardless of PD-L1 expression or unfavorable tumor microenvironments.

Regarding safety

All of the severe treatment-related adverse events were reported in 6 patients and included atrial fibrillation; hyperglycemia; and acute kidney injury, blood creatinine increase, dyspnea, hypernatremia, and hypoxia.

The future

The ongoing phase III PIVOT 1O 001 trial is evaluating NKTR-214in combination with Opdivo versus Opdivo alone as frontline therapy for patients with advanced melanoma.

To conclude

The best treatment for a cancer patient is to get the most advanced cancer drugs in advanced stages of development. There, the hope and the chance to extend life go far beyond the standard protocols.

Contact us to find out what is the best treatment for YOU

TRIAL•IN Pharma
Do not give up on life!
Contact us 24/7 for free service matching:
Call center +44.2082.426.039
www.trial-in.com

For further reading

No Cost service compatibility check
Please fill in the details and we will back to you as soon as possible

Improving therapeutic success, extending life and quality of life are our main business. We extend to metastatic cancer patients and patients with brain tumors, the most advanced treatment options in the world and the best experts in Israel and abroad.

Article categories

קטגוריות המאמרים

Popular topics